Crossject Société Anonyme (ALCJ.PA)
Crossject Société Anonyme
6 Rue Pauline Kergomard
Dijon 21000
France
33 3 80 54 98 50
https://www.crossject.com
Sector(es): Healthcare
Industria: Medical Instruments & Supplies
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Patrick Alexandre | Co-Founder, CEO & Chairman of the Executive Board | N/D | N/D | N/D |
| Dr. Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Executive Board | N/D | N/D | N/D |
| Mr. Henri de Parseval | COO of Engineering & Industry and Member of Executive Board | N/D | N/D | N/D |
| Mr. Olivier Giré | COO of Specialty Pharma & Member of Executive Board | N/D | N/D | N/D |
Descripción
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
Gestión corporativa
La calificación ISS Governance QuickScore de Crossject Société Anonyme a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
